Jamile Shammo to Aged
This is a "connection" page, showing publications Jamile Shammo has written about Aged.
Connection Strength
0.211
-
Hereditary Hemochromatosis Manifesting After Treatment of Paroxysmal Nocturnal Hemoglobinuria With Eculizumab. Clin Lymphoma Myeloma Leuk. 2018 01; 18(1):e9-e12.
Score: 0.058
-
Clinical roundtable monograph. MDS classification and risk stratification. Clin Adv Hematol Oncol. 2009 Jul; 7(7):S8-12.
Score: 0.032
-
Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database. Leuk Res. 2021 10; 109:106629.
Score: 0.019
-
Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. Blood. 2020 05 07; 135(19):1696-1703.
Score: 0.017
-
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q). J Hematol Oncol. 2017 06 26; 10(1):131.
Score: 0.014
-
Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. Int J Mol Sci. 2017 Apr 14; 18(4).
Score: 0.014
-
Impact of insulin-like growth factor 1 and insulin-like growth factor binding proteins on outcomes in acute myeloid leukemia. Leuk Lymphoma. 2015; 56(11):3135-42.
Score: 0.012
-
Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. Leuk Lymphoma. 2013 Sep; 54(9):1989-95.
Score: 0.010
-
Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma. Leuk Lymphoma. 2011 Nov; 52(11):2097-104.
Score: 0.009
-
Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma. Clin Lymphoma Myeloma Leuk. 2011 Dec; 11(6):467-74.
Score: 0.009
-
Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol. 2010 Jan 20; 28(3):437-44.
Score: 0.008
-
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008 Jan 01; 111(1):86-93.
Score: 0.007